Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SHTN1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SHTN1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SHTN1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SHTN1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SHTN1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SHTN1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SHTN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070157 | Liver | NAFLD | actin filament organization | 78/1882 | 442/18723 | 5.44e-07 | 3.21e-05 | 78 |
GO:00071636 | Liver | NAFLD | establishment or maintenance of cell polarity | 46/1882 | 218/18723 | 8.80e-07 | 4.60e-05 | 46 |
GO:00300106 | Liver | NAFLD | establishment of cell polarity | 34/1882 | 143/18723 | 1.41e-06 | 6.56e-05 | 34 |
GO:20001145 | Liver | NAFLD | regulation of establishment of cell polarity | 11/1882 | 22/18723 | 2.54e-06 | 1.06e-04 | 11 |
GO:00072664 | Liver | NAFLD | Rho protein signal transduction | 31/1882 | 137/18723 | 1.19e-05 | 3.67e-04 | 31 |
GO:00328784 | Liver | NAFLD | regulation of establishment or maintenance of cell polarity | 11/1882 | 25/18723 | 1.20e-05 | 3.69e-04 | 11 |
GO:00485884 | Liver | NAFLD | developmental cell growth | 45/1882 | 234/18723 | 1.50e-05 | 4.38e-04 | 45 |
GO:00313465 | Liver | NAFLD | positive regulation of cell projection organization | 57/1882 | 353/18723 | 2.19e-04 | 3.73e-03 | 57 |
GO:00015585 | Liver | NAFLD | regulation of cell growth | 63/1882 | 414/18723 | 5.50e-04 | 7.46e-03 | 63 |
GO:00486754 | Liver | NAFLD | axon extension | 24/1882 | 120/18723 | 7.74e-04 | 9.73e-03 | 24 |
GO:00605604 | Liver | NAFLD | developmental growth involved in morphogenesis | 39/1882 | 234/18723 | 1.11e-03 | 1.28e-02 | 39 |
GO:00615727 | Liver | NAFLD | actin filament bundle organization | 29/1882 | 161/18723 | 1.37e-03 | 1.54e-02 | 29 |
GO:19901383 | Liver | NAFLD | neuron projection extension | 30/1882 | 172/18723 | 1.93e-03 | 1.94e-02 | 30 |
GO:00109755 | Liver | NAFLD | regulation of neuron projection development | 64/1882 | 445/18723 | 2.12e-03 | 2.08e-02 | 64 |
GO:0032488 | Liver | NAFLD | Cdc42 protein signal transduction | 6/1882 | 15/18723 | 2.30e-03 | 2.19e-02 | 6 |
GO:00457734 | Liver | NAFLD | positive regulation of axon extension | 11/1882 | 42/18723 | 2.32e-03 | 2.19e-02 | 11 |
GO:00459275 | Liver | NAFLD | positive regulation of growth | 40/1882 | 259/18723 | 4.00e-03 | 3.35e-02 | 40 |
GO:00325356 | Liver | NAFLD | regulation of cellular component size | 55/1882 | 383/18723 | 4.31e-03 | 3.55e-02 | 55 |
GO:00303075 | Liver | NAFLD | positive regulation of cell growth | 28/1882 | 166/18723 | 4.35e-03 | 3.57e-02 | 28 |
GO:00486384 | Liver | NAFLD | regulation of developmental growth | 48/1882 | 330/18723 | 5.74e-03 | 4.37e-02 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SHTN1 | SNV | Missense_Mutation | | c.1631C>T | p.Pro544Leu | p.P544L | A0MZ66 | protein_coding | deleterious(0) | benign(0.001) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SHTN1 | SNV | Missense_Mutation | novel | c.975G>C | p.Gln325His | p.Q325H | A0MZ66 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SHTN1 | insertion | Nonsense_Mutation | novel | c.1034_1035insTTCCATGCTATTCTCATGATAGTGAATCTCATGAGATCTGATG | p.Asn346SerfsTer6 | p.N346Sfs*6 | A0MZ66 | protein_coding | | | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
SHTN1 | insertion | Nonsense_Mutation | novel | c.1031_1032insTTCTCTCTTCCCTGCTGCCATGTAAGATGTGACTTGCTTCTCCTT | p.Arg344_Val345insSerLeuPheProAlaAlaMetTerAspValThrCysPheSerLeu | p.R344_V345insSLFPAAM*DVTCFSL | A0MZ66 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SHTN1 | SNV | Missense_Mutation | novel | c.117C>A | p.Asp39Glu | p.D39E | A0MZ66 | protein_coding | tolerated(0.29) | possibly_damaging(0.496) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
SHTN1 | insertion | In_Frame_Ins | novel | c.465_466insTCTGAAATT | p.Gln155_Glu156insSerGluIle | p.Q155_E156insSEI | A0MZ66 | protein_coding | | | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SHTN1 | SNV | Missense_Mutation | novel | c.443N>A | p.Arg148Gln | p.R148Q | A0MZ66 | protein_coding | tolerated(0.6) | benign(0.006) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SHTN1 | SNV | Missense_Mutation | | c.1654N>C | p.Ser552Arg | p.S552R | A0MZ66 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SHTN1 | SNV | Missense_Mutation | | c.716N>C | p.Phe239Ser | p.F239S | A0MZ66 | protein_coding | deleterious(0.01) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SHTN1 | SNV | Missense_Mutation | novel | c.452N>G | p.Ile151Ser | p.I151S | A0MZ66 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |